Protecting Our Pharmaceutical Supply Chain from China Act of 2020
Latest action · Jul 13, 2020 Referred to the Subcommittee on Oversight and Investigations.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedApr 10, 2020
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Protecting Our Pharmaceutical Supply Chain from China Act of 2020
This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing Chinese ingredients, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.
Cosponsors 11
Members who signed on, in the order they did. Signatures ran from Apr 10, 2020 to Oct 27, 2020; 3 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-NY | Elise M. Stefanik | Original | Apr 10, 2020 |
| R-WY | Liz Cheney | Original | Apr 10, 2020 |
| R-NC | Ted Budd | Original | Apr 10, 2020 |
| D-NJ | Jefferson Van Drew | Apr 28, 2020 | |
| R-FL | Bill Posey | May 8, 2020 | |
| R-MO | Vicky Hartzler | May 8, 2020 | |
| R-PR | Jenniffer González-Colón | May 15, 2020 | |
| R-AZ | Andy Biggs | May 22, 2020 | |
| R-AZ | Debbie Lesko | Jun 8, 2020 | |
| R-IN | James R. Baird | Jul 1, 2020 | |
| R-OH | Michael R. Turner | Oct 27, 2020 |
Committees 4
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Apr 10, 2020 |
| House | Ways and Means Committee | Referred Apr 10, 2020 |
| Health Subcommittee | Referred Apr 10, 2020 | |
| House | Armed Services Committee | Referred Apr 10, 2020 |
| House | Veterans' Affairs Committee | Referred Apr 10, 2020 |
| Oversight and Investigations Subcommittee | Referred Jul 13, 2020 |
Actions 4
Everything that happened, newest first.
- Jul 13, 2020Referred to the Subcommittee on Oversight and Investigations.
- Apr 10, 2020Introduced in House
- Apr 10, 2020Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Armed Services, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Apr 10, 2020Referred to the Subcommittee on Health.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 166, no. 69, April 10, 2020, page H1883.
CRS reports 2
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 2
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R46304 | COVID-19: China Medical Supply Chains and Broader Trade Issues | Report | Dec 23, 2020 |
| R46507 | FDA’s Role in the Medical Product Supply Chain and Considerations During COVID-19 Archived | Report | Sep 1, 2020 |
Related bills 2
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 3537 | Protecting Our Pharmaceutical Supply Chain from China Act of 2020 | Identical bill | Mar 19, 2020 |
| S 3635 | Protecting Our Pharmaceutical Supply Chain from China Act of 2020 | Related bill | May 6, 2020 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To require the Secretary of Health and Human Services to maintain a list of the country of origin of all drugs marketed in the United States, to ban the use of Federal funds for the purchase of drugs manufactured in China, and for other purposes.
- Short Title(s) as Introduced
- Protecting Our Pharmaceutical Supply Chain from China Act of 2020
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Asia
- Business expenses
- China
- Drug safety, medical device, and laboratory regulation
- Government information and archives
- Health
- Health care costs and insurance
- Health programs administration and funding
- Health technology, devices, supplies
- Income tax deductions
- Manufacturing
- Military medicine
- Military procurement, research, weapons development
- Prescription drugs
- Public contracts and procurement
- Trade restrictions
- Veterans' medical care
Text 1
Each version as it was printed, newest first.
- Apr 10, 2020Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.